NCT03101111View on ClinicalTrials.gov

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions
Chikungunya
Interventions
BIOLOGICAL

MV-CHIK

Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose

BIOLOGICAL

MMR-vaccine

Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose

Trial Locations (1)

00936-5067

University of Puerto Rico - Medical Sciences Campus, San Juan

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Themis Bioscience GmbH

INDUSTRY

NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area | Biotech Hunter | Biotech Hunter